Biotech Values

[GD]

PTLA: Bevyxxa's different pharmacokinetics , that is why Bevyxxa succeed
while Eilquis and Xarelto failed. B is a strong competition to Eilquis and
Xarelto in the future just because Bevyxxa's different pharmacokinetics.
PTLA is a small company, they can not get lucky with "new" FDA's
approval with a good broad label. Data is what FDA looking at, IMO.
I respect your opinion, we may see the results of launch and
uptake by year end.